Fast Market Research recommends "Mexico Pharmaceuticals & Healthcare Report Q2 2014" from Business Monitor International, now available

Boston, MA -- (SBWire) -- 02/25/2014 --We identified Mexico as 'the most promising emerging pharmaceutical market' in September 2013, Shortly after this, the approval of the energy reform bill reinforced our view that, over the long term, healthier fiscal revenue will encourage the government to further increase public healthcare spending and improve national medical service standards. Multinational pharmaceutical companies will have more opportunities to fully capitalise on Mexico's strong pharmaceuticals and healthcare market growth.

Headline Expenditure Projections

- Pharmaceuticals: MXN192.41bn (US$14.97bn) in 2013 to MXN210.40bn (US$16.63bn) in 2014; +9.3% in local currency terms and +11.1% in US dollar terms. Forecast increased from Q114 due to a positive macroeconomic outlook.
- Healthcare: MXN1,030.95bn (US$80.23bn) in 2013 to MXN1,120.06n (US$88.54bn) in 2014; +8.6% in local currency terms and +10.4% in US dollar terms. Forecast increased from Q114 due to changes to macroeconomic forecasts.

View Full Report Details and Table of Contents

Risk/Reward Rating: Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fourth-most attractive pharmaceutical market in the Americas. We have reweighted the RRR components to improve the tool, and adjusted scores for all markets in the Pharmaceuticals & Healthcare reports.

Key Trends And Developments

- In January 2014, Mexico's Federal Commission for Protection Against Health Risks (COFEPRIS) and the Confederation of Customs Brokers Associations of Mexico (CAAAREM) renewed the cooperation agreement to accelerate health sector control in foreign trade for 2014.
- In December 2013, COFEPRIS reported that it approved a total of 101 new molecules in the period between 2012 and 2013.
- In December 2013, Mexico's National Institute of Medical Sciences and Nutrition became the first hospital in Latin America to secure a certificate from the Association for the Accreditation Program of Human Research Protection (AAHRPP).
- In December 2013, the Supreme Court of Justice (Suprema Corte de Justicia de la Nacion, SCJN), the highest court of Mexico, made the final decision on a dispute between Roche and the Mexican generic drugmaker Probiomed. COFEPRIS must make the final judgement on the Roche - Probiomed case to ensure that Probiomed's version meets all the legal requirements in terms of safety, quality and efficacy. This means that COFEPRIS must decide whether clinical studies are needed, which is the main point of conflict between Roche and Probiomed.
- In November 2013, Bayer planned to open a new office in the capital of Mexico, Mexico City.
- In November 2013, Wal-Mart de Mexico y Centroamerica signed an agreement with the Mexican Association of Interchangeable Generics Manufacturers (AMEGI) to secure the institution's support in generic drug issues.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Australia Pharmaceuticals & Healthcare Report Q2 2014
- Nigeria Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Algeria Pharmaceuticals & Healthcare Report Q2 2014
- South Korea Pharmaceuticals & Healthcare Report Q2 2014
- Malaysia Pharmaceuticals & Healthcare Report Q1 2014
- Furiex Pharmaceuticals, Inc. (FURX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Bayer Healthcare Pharmaceuticals - SWOT, Strategy and Corporate Finance Report
- Bayer HealthCare Pharmaceuticals Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile